Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Daiichi Sankyo
2017-09-15 17:45:01
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
Daiichi Sankyo
2017-09-11 17:45:01
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for
Daiichi Sankyo Showcases New Insights on Multiple Oncology Compounds at the European Society for Medical Oncology (ESMO) 2017 Congress
Daiichi Sankyo
2017-08-31 17:45:01
Daiichi Sankyo Showcases New Insights on Multiple Oncology Compounds at the European Society for Medical
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
Daiichi Sankyo
2017-08-29 17:45:01
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer
Daiichi Sankyo
2017-08-29 17:45:01
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast
Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
Daiichi Sankyo
2017-08-29 17:45:01
Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Daiichi Sankyo
2017-08-29 17:45:01
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET
New sub-analysis data highlights the benefit of LIXIANA®▼ (edoxaban) over warfarin in NVAF patients according to more comprehensive stroke risk scoring
Daiichi Sankyo
2017-08-30 17:45:01
New sub-analysis data highlights the benefit of LIXIANA®▼ (edoxaban) over warfarin in NVAF patients according
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
Daiichi Sankyo
2017-07-19 17:45:01
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody
CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Daiichi Sankyo
2017-07-31 14:04:21
CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) in Patients with Atrial
More Stories
